SF3B4-mediated alternative splicing in cancer development and progression
Cancer Letters,
Год журнала:
2025,
Номер
unknown, С. 217597 - 217597
Опубликована: Март 1, 2025
Язык: Английский
Long-term Outcomes for Neoadjuvant Versus Adjuvant Chemotherapy in ER+/HER2− Locally Advanced Breast Cancer
Annals of Surgical Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 22, 2025
Язык: Английский
Deciphering peripheral neuroimmune crosstalk for translational therapeutics
Journal of Translational Internal Medicine,
Год журнала:
2025,
Номер
13(1), С. 4 - 6
Опубликована: Фев. 1, 2025
Язык: Английский
Efficacy and safety of pyrotinib in the treatment of HER2-positive liver metastatic advanced breast cancer
Frontiers in Oncology,
Год журнала:
2025,
Номер
15
Опубликована: Апрель 8, 2025
This
study
aimed
to
evaluate
the
efficacy
and
safety
of
pyrotinib
in
treatment
HER2-positive
breast
cancer
patients
with
without
liver
metastasis.
A
retrospective
analysis
was
conducted
on
91
advanced
cancer,
who
were
treated
between
March
2019
April
2022.
The
categorized
into
two
groups
based
presence
or
absence
metastases,
their
overall
survival
(OS),
progression-free
(PFS),
response
compared.
Adverse
effects
analyzed
assess
pyrotinib.
cohort
include
29
metastasis
62
without.
median
significantly
shorter
group
(15.8
months)
than
that
non-liver
(31.4
months,
P
=
0.0036).
statistically
significant
difference
observed
PFS
(8.7
vs.
18.4
(P
0.0272).
Univariate
revealed
younger
age
(<60
years)
<
0.0001),
negative
progesterone
receptor
expression
0.0028),
higher
Ki67
levels
lymph
node
0.0001)
more
likely
benefit
from
treatment.
Comparative
showed
incidence
rates
anemia
(58.6%
40.3%)
elevated
aspartate
transaminase
level
(31.0%
vs
8.1%)
compared
0.05).
Pyrotinib-based
therapy
is
efficacious
safe
for
while
further
large-scale
clinical
trials
are
warranted
validate
these
results.
Язык: Английский
Safety and necessity of omitting mediastinal lymph node dissection in cN0/N1 non-small cell lung cancer after neoadjuvant immunotherapy
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Апрель 29, 2025
Lymph
nodes
are
crucial
for
perioperative
immunotherapy
but
have
to
be
completely
resected
in
surgery.
Trials
evaluating
the
safety
and
necessity
of
omitting
systemic
mediastinal
lymph
node
(mLN)
dissection
non-small
cell
lung
cancer
(NSCLC)
still
absent.
cN0/N1
NSCLC
patients
who
received
neoadjuvant
radical
surgery
were
retrospectively
collected
from
three
institutions.
Restricted
cubic
spline
regression
receiver
operating
characteristic
curve
used
analyze
association
between
mLN
number
survival
outcomes.
Confounding
factors
selective
groups
adjusted
by
inverse
probability
treatment
weighting
(IPTW).
The
characteristics
memory
CD8+
T
cells
immunotherapy-treated
identified
single-cell
RNA
T-cell
receptor
sequencing
(scRNA/TCR-seq)
data
retrieved
GSE185206.
From
2019
2021,
131
neoadjuvant-treated
collected.
clearance
rate
was
98.5%
whole
cohort
100%
with
radiologically
confirmed
complete
response.
Resected
counts
irrelevant
local
recurrence,
distant
metastasis,
or
death.
Compared
dissection,
did
not
show
any
benefit
showed
slightly
higher
postoperative
recurrence
risk
both
unadjusted
IPTW-adjusted
cohorts.
scRNA/TCR-seq
that
stem-like
exhausted
progenitors
tumor-specific
lymphocytes
primary
tumors
abundantly
enriched
mLN.
Omitting
safe
immunotherapy.
Excessive
may
disrupt
repertoire
consequently
impair
efficacy
adjuvant
Язык: Английский
Lactic acid metabolism: gynecological cancer's Achilles’ heel
Discover Oncology,
Год журнала:
2025,
Номер
16(1)
Опубликована: Май 2, 2025
Язык: Английский
Clinical approaches to overcome PARP inhibitor resistance
Molecular Cancer,
Год журнала:
2025,
Номер
24(1)
Опубликована: Май 30, 2025
PARP
inhibitors
have
profoundly
changed
treatment
options
for
cancers
with
homologous
recombination
repair
defects,
especially
those
carrying
BRCA1/2
mutations.
However,
the
development
of
resistance
to
these
presents
a
significant
clinical
challenge
as
it
limits
long-term
effectiveness.
This
review
provides
an
overview
current
understanding
mechanisms
and
explores
strategies
overcome
challenges.
We
discuss
basis
synthetic
lethality
induced
by
detail
diverse
affecting
inhibitors,
including
restoration,
reduced
trapping,
enhanced
drug
efflux,
replication
fork
stabilization.
The
then
considers
approaches
combat
resistance,
focusing
on
combination
therapies
immune
checkpoint
DNA
damage
response
epigenetic
drugs.
also
highlight
ongoing
trials
potential
biomarkers
predicting
resistance.
concludes
outlining
future
research
directions,
emphasizing
need
longitudinal
studies,
advanced
monitoring
technologies,
novel
strategies.
By
tackling
inhibitor
this
seeks
aid
in
more
effective
cancer
therapies,
improve
outcomes
patients
recombination-deficient
tumors.
Язык: Английский
Integrated Multiomics Analysis and Machine Learning Approaches in Bladder Cancer: Unveiling the Impact of Immunogenic Cell Death and Its Key Gene SLC2A3 on Prognosis and Personalized Treatment Strategies
ACS Omega,
Год журнала:
2025,
Номер
unknown
Опубликована: Июнь 4, 2025
Язык: Английский